NeoGenomics Launches PanTracer Tissue and PanTracer Tissue HRD Assays (ir.neogenomics.com)

• PanTracer Tissue profiles over 500 cancer genes and returns results in 8 days.
• HRD option includes BRCA mutation and genomic instability score for PARP inhibitor therapy.
• Assay replaces NeoComprehensive Solid Tumor and was previewed at ASCO 2025.

"NeoGenomics announced on June 30, 2025, the launch of PanTracer Tissue and PanTracer Tissue + HRD, next-generation solid tumor profiling assays. They analyze over 500 cancer-related genes with results in as little as 8 days. The HRD add-on includes BRCA mutation status and a genomic instability score for PARP inhibitor therapy selection. The assays replace the previous NeoComprehensive Solid Tumor platform and were previewed at ASCO 2025."